---
document_datetime: 2024-02-13 12:45:10
document_pages: 15
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zutectra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zutectra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 21.6907708
conversion_datetime: 2025-12-19 13:50:26.626726
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zutectra

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0064               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                       | 12/02/2024                          |                                             | PL                               |           |
| IAIN/0063            | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - | 29/11/2023                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | of an updated/amended PMF when changes not affect the properties of the FP                                                                                                                                                                                      |            |     |    | Inclusion do   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|----------------|
| N/0062    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                | 06/11/2023 |     | PL |                |
| IAIN/0061 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                  | 13/10/2023 | n/a |    |                |
| II/0058   | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an protocol | 14/04/2023 | n/a |    | approved       |
| IAIN/0059 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                  | 14/03/2023 | n/a |    |                |
| IAIN/0057 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                  | 29/11/2022 | n/a |    |                |

<div style=\"page-break-after: always\"></div>

| IA/0056   | B.II.d.2.e - Change in test procedure for the finished product - Update of the test procedure to comply with the updated general monograph in the Ph. Eur.                                                                                                                                                                                                                                                                                                                                                                        | 25/11/2022   | n/a        |                        |                                                                         |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------------------------------------------|
| IB/0055/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.b - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - First-time inclusion of a new PMF NOT affecting the properties of the FP | 31/10/2022   | n/a        |                        |                                                                         |
| N/0054    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                  | 29/08/2022   | 24/04/2023 | PL                     |                                                                         |
| IAIN/0053 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                    | 17/05/2022   | n/a        |                        |                                                                         |
| IB/0052   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                    | 04/03/2022   | 24/04/2023 | SmPC, Labelling and PL | PI has been aligned with the latest QRD template (version 10.2, rev. 1) |
| II/0050   | B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative                                                                                                                                                                                                                                                                                                                                                                                                                               | 10/02/2022   | n/a        |                        |                                                                         |

<div style=\"page-break-after: always\"></div>

|                    | composition - Sterile medicinal products and biological/immunological medicinal products                                                                                                                                                                                 |            |     |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| II/0051            | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol | 13/01/2022 | n/a |                                   |
| IAIN/0049          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                           | 10/08/2021 | n/a |                                   |
| PSUSA/1631/ 202011 | Periodic Safety Update EU Single assessment - human hepatitis B immunoglobulin                                                                                                                                                                                           | 08/07/2021 | n/a | PRAC Recommendation - maintenance |
| IAIN/0048          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                           | 17/03/2021 | n/a |                                   |
| IAIN/0046          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                           | 09/07/2020 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0045   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                       | 13/03/2020   | n/a        |    |           |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|-----------|
| IB/0044     | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                     | 10/03/2020   | n/a        |    |           |
| IB/0043     | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                           | 07/10/2019   | n/a        |    |           |
|             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                       | 01/08/2019   | n/a        |    | IAIN/0041 |
| N/0042      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                     | 31/07/2019   | 24/04/2023 | PL |           |
| IAIN/0040/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.V.a.1.d - PMF - Inclusion of a new, updated or | 15/03/2019   | n/a        |    |           |

<div style=\"page-break-after: always\"></div>

|                    | amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                |            |            |                                  |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| N/0039             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                             | 05/10/2018 | 11/04/2019 | PL                               |                                   |
| IAIN/0038          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                               | 26/07/2018 | n/a        |                                  |                                   |
| PSUSA/1631/ 201711 | Periodic Safety Update EU Single assessment - human hepatitis B immunoglobulin                                                                                                                                                                                                                                                               | 12/07/2018 | n/a        |                                  | PRAC Recommendation - maintenance |
| WS/1360            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 17/05/2018 | 11/04/2019 | SmPC, Annex II, Labelling and PL |                                   |
| IAIN/0037          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                               | 20/03/2018 | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0034          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 12/10/2017   | n/a   |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IA/0033/G          | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State | 28/07/2017   | n/a   |                                   |
| PSUSA/1631/ 201611 | Periodic Safety Update EU Single assessment - human hepatitis B immunoglobulin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 06/07/2017   | n/a   | PRAC Recommendation - maintenance |
| IAIN/0032          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 10/03/2017   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|                    | of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                     |            |            |                       |                                                                                                    |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------|
| IAIN/0030          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 03/08/2016 | n/a        |                       |                                                                                                    |
| N/0029             | Update of the package leaflet with revised contact details of the local representative for Slovenia. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                          | 01/08/2016 | 11/04/2019 | PL                    |                                                                                                    |
| PSUSA/1631/ 201511 | Periodic Safety Update EU Single assessment - human hepatitis B immunoglobulin                                                                                                                                                                 | 07/07/2016 | n/a        |                       | PRAC Recommendation - maintenance                                                                  |
| IAIN/0028          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 09/03/2016 | n/a        |                       |                                                                                                    |
| IB/0026            | B.II.d.2.e - Change in test procedure for the finished product - Update of the test procedure to comply with the updated general monograph in the Ph. Eur.                                                                                     | 11/01/2016 | n/a        |                       |                                                                                                    |
| II/0024            | Extension of Indication to Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA                                                                                                                                             | 19/11/2015 | 16/12/2015 | SmPC, Annex II and PL | For further information please refer to the published Assessment Report: Zutectra H-1089-II-24-AR. |

<div style=\"page-break-after: always\"></div>

|                    | negative patients at least one week - instead of the approved at least 6 months - after liver transplantation for hepatitis B induced liver failure. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity of this procedure to update the Annex II in compliance with the QRD template version 9.1. An updated RMP version 2 has been agreed. The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |     |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IAIN/0025          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 16/10/2015 | n/a |                                   |
| PSUSA/1631/ 201411 | Periodic Safety Update EU Single assessment - human hepatitis B immunoglobulin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 09/07/2015 | n/a | PRAC Recommendation - maintenance |
| IAIN/0023          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 13/03/2015 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                     |                                                                                                                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-------------------------------------------------------------------------------------------------------------------|
| IB/0021   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 25/02/2015 | n/a        |                     |                                                                                                                   |
| N/0020    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22/01/2015 | 16/12/2015 | PL                  |                                                                                                                   |
| IA/0019/G | This was an application for a group of variations. B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 12/12/2014 | n/a        |                     |                                                                                                                   |
| R/0015    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/07/2014 | 16/09/2014 | SmPC, Labelling and | Based on the CHMP review of data on quality, safety and efficacy, the CHMP considered by consensus that the risk- |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                |            |            | PL       | benefit balance of Zutectra in the prevention of hepatitis B virus re-infection in HBV-DNA negative patients â‰¥ 6 months after liver transplantation for hepatitis B induced liver failure remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0018          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                             | 01/09/2014 | n/a        |          |                                                                                                                                                                                                                                                                                                              |
| PSUSA/1631/ 201311 | Periodic Safety Update EU Single assessment - human hepatitis B immunoglobulin                                                                                                                                                                 | 10/07/2014 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                            |
| IAIN/0016          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 05/03/2014 | n/a        |          |                                                                                                                                                                                                                                                                                                              |
| PSUSA/1631/ 201305 | Periodic Safety Update EU Single assessment - human hepatitis B immunoglobulin                                                                                                                                                                 | 09/01/2014 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                            |
| IA/0014/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                 | 18/12/2013 | 06/06/2014 | Annex II |                                                                                                                                                                                                                                                                                                              |
| II/0011            | Submission of validation data regarding the removal of thrombosis generating agents during the                                                                                                                                                 | 24/10/2013 | n/a        |          |                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         | manufacturing process to comply with the revised Eur. Ph. monograph of Human Normal Immunoglobulin (0338). B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation                                                                                                                                                                                                      |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0012  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                | 19/09/2013 | 06/06/2014 | PL                               | Inclusion of an additional local representative of the MAH for the new Member State, Croatia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0008 | Update of sections 4.8 and 5.1 of the SmPC and consequential changes to section 4 of the PIL to include the final results from study 974 and study 978, a PASS, in order to fulfil MEA 002.2. Furthermore, the PI is being brought in line with the latest QRD template. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 27/06/2013 | 06/06/2014 | SmPC, Annex II, Labelling and PL | In study 974, an open, prospective, single-arm clinical study investigating the feasibility of home self- administration, efficacy and safety of SC Zutectra in a population of stable patients, no re-infection was observed and no serious adverse events treatment related were reported. In study 978, a non-interventional post-authorisation study evaluating compliance of patients using SC Zutectra as home self-treatment, compliance according to anti-HBs serum levels was shown for 93% of patients, no treatment failure was observed and no serious adverse events treatment related were reported. Information regarding the results of these two studies was |
| II/0009 | Change in the manufacturing process of the active substance. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal                                                                                                                                                                                                       | 30/05/2013 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | product and is not related to a protocol                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |          |                                                                                                                                            |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0010 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                        | 26/03/2013 | n/a        |          |                                                                                                                                            |
| N/0007    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                      | 20/11/2012 | 06/06/2014 | PL       | Update of the list of local representatives for Greece, France and Romania.                                                                |
| IAIN/0006 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                        | 22/06/2012 | n/a        |          |                                                                                                                                            |
| N/0005    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                      | 13/10/2011 | n/a        | PL       | Update of the local representatives contact details for Denmark, France, Island, Norway, Portugal, Finland, Sweden and the United Kingdom. |
| IA/0004/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance | 12/08/2011 | n/a        | Annex II |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |      |                                                                                                                                                                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0003/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes | 17/12/2010 | n/a |      |                                                                                                                                                                                              |
| N/0002    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 15/12/2010 | n/a | PL   | Update of the list of the local representatives for Belgium, Spain, Luxembourg, Malta, the Netherlands and Portugal. A minor linguistic change was also made in the Italian package leaflet. |
| IB/0001   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Extension of storage period of a biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 29/07/2010 | n/a | SmPC |                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->